» Articles » PMID: 31651270

Burden of Neurological and Neurocognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE): a Cross-sectional Study

Abstract

Background: Children with sickle cell anemia (SCA) are highly susceptible to stroke and other manifestations of pediatric cerebral vasculopathy. Detailed evaluations in sub-Saharan Africa are limited.

Methods: We aimed to establish the frequency and types of pediatric brain injury in a cross-sectional study at a large SCA clinic in Kampala, Uganda in a randomly selected sample of 265 patients with HbSS ages 1-12 years. Brain injury was defined as one or more abnormality on standardized testing: neurocognitive impairment using an age-appropriate test battery, prior stroke by examination or transcranial Doppler (TCD) velocities associated with stroke risk in children with SCA (cerebral arterial time averaged mean maximum velocity ≥ 170 cm/second).

Results: Mean age was 5.5 ± 2.9 years; 52.3% were male. Mean hemoglobin was 7.3 ± 1.01 g/dl; 76.4% had hemoglobin < 8.0 g/dl. Using established international standards, 14.7% were malnourished, and was more common in children ages 5-12. Overall, 57 (21.5%) subjects had one to three abnormal primary testing. Neurocognitive dysfunction was found in 27, while prior stroke was detected in 15 (5.7%). The most frequent abnormality was elevated TCD velocity 43 (18.1%), of which five (2.1%) were in the highest velocity range of abnormal. Only impaired neurocognitive dysfunction increased with age (OR 1.44, 95%CI 1.23-1.68), p < 0.001). In univariate models, malnutrition defined as wasting (weight-for-height ≤ -2SD), but not sex or hemoglobin, was modestly related to elevated TCD (OR 1.37, 95%CI 1.01-1.86, p = 0.04). In adjusted models, neurocognitive dysfunction was strongly related to prior stroke (OR 6.88, 95%CI 1.95-24.3, p = .003) and to abnormal TCD (OR 4.37, 95%CI 1.30, p = 0.02). In a subset of 81 subjects who were enriched for other abnormal results, magnetic resonance imaging and angiography (MRI/MRA) detected infarcts and/or arterial stenosis in 52%. Thirteen subjects (25%) with abnormal imaging had no other abnormalities detected.

Conclusions: The high frequency of neurocognitive impairment or other abnormal results describes a large burden of pediatric SCA brain disease in Uganda. Evaluation by any single modality would have underestimated the impact of SCA. Testing the impact of hydroxyurea or other available disease-modifying interventions for reducing or preventing SCA brain effects is warranted.

Citing Articles

Incident Stroke in Pediatric Sickle cell Anemia Despite Overall Improved Transcranial Doppler Velocity in a Ugandan Hydroxyurea Trial: Antecedent and ongoing risks.

Wambaka B, Mpungu A, Mboizi V, Kalibbala D, Nambatya G, Murungi S medRxiv. 2025; .

PMID: 39974085 PMC: 11838932. DOI: 10.1101/2025.01.28.25320389.


Neurocognitive Profile and Associated Factors Among Children Affected by Sickle Cell Disease in Kinshasa, Democratic Republic of Congo: A Cross-Sectional Study.

Lelo P, Kitetele F, Kunyu M, Akele C, Okitundu D, Sam D Children (Basel). 2025; 11(12.

PMID: 39767950 PMC: 11726882. DOI: 10.3390/children11121521.


Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial.

Mboizi V, Nabaggala C, Munube D, Ssenkusu J, Kasirye P, Kamya S Contemp Clin Trials Commun. 2024; 42:101404.

PMID: 39717517 PMC: 11664125. DOI: 10.1016/j.conctc.2024.101404.


The Association Between Sickle Cell Anemia and Cognitive Dysfunction: A Systematic Review.

Alpakra M, Hamed N, Almakki Z, Al Bakrah E Cureus. 2024; 16(9):e69104.

PMID: 39391457 PMC: 11466366. DOI: 10.7759/cureus.69104.


Academic achievement in Ugandan children with sickle cell anaemia: A cross-sectional study.

Naggayi S, Bangirana P, Opoka R, Ouma S, Nyangoma B, Birabwa A medRxiv. 2024; .

PMID: 39040208 PMC: 11261957. DOI: 10.1101/2024.07.08.24309901.


References
1.
Yawn B, Buchanan G, Afenyi-Annan A, Ballas S, Hassell K, James A . Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312(10):1033-48. DOI: 10.1001/jama.2014.10517. View

2.
Hijmans C, Grootenhuis M, Oosterlaan J, Heijboer H, Peters M, Fijnvandraat K . Neurocognitive deficits in children with sickle cell disease are associated with the severity of anemia. Pediatr Blood Cancer. 2011; 57(2):297-302. DOI: 10.1002/pbc.22892. View

3.
Galadanci N, Abdullahi S, Vance L, Tabari A, Ali S, Belonwu R . Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol. 2017; 92(8):780-788. PMC: 5523858. DOI: 10.1002/ajh.24770. View

4.
Rankine-Mullings A, Morrison-Levy N, Soares D, Aldred K, King L, Ali S . Transcranial Doppler velocity among Jamaican children with sickle cell anaemia: determining the significance of haematological values and nutrition. Br J Haematol. 2018; 181(2):242-251. DOI: 10.1111/bjh.15162. View

5.
Galadanci N, Abdullahi S, Tabari M, Abubakar S, Belonwu R, Salihu A . Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial. Pediatr Blood Cancer. 2014; 62(3):395-401. PMC: 4304992. DOI: 10.1002/pbc.25289. View